Mandate

Vinge advises FSN Capital in connection with the acquisition of Seriline

Vinge advises FSN Capital in connection with the acquisition of a majority stake in Seriline AB from its current shareholders, who will retain a sizable stake in the company.

Serline was founded in 1990 and is a provider of Identity and Access Management (IAM) solutions. Seriline offers proprietary software, online solutions, hardware and services that simplify the flow to creating user-friendly processes for confidentiality and integrity management of identities. Seriline has 29 FTEs and had SEK 84m in sales in 2021. The company is expected to be the initial platform in FSN’s buy-and-build strategy to create a Nordic cybersecurity leader within IAM.

Established in 1999, FSN Capital Partners is a leading Northern European private equity firm and investment advisor to the FSN Capital Funds, with €4 billion under management. FSN Capital Funds make control investments in growth-oriented Northern European companies, to support further growth and to transform companies into more sustainable, competitive, international, and profitable entities. 

Vinge’s team mainly consisted of Johan Winnerblad, Maria Dahlin Kolvik, Eléonore Friberg and Ebba Nyberg (M&A), Mathilda Persson and Karolina Fuhrman (IT/GDPR), Martin Boström (Commercial agreements), Felix Möller (Bank and Finance), Gustav Lindgren (Arbetsrätt), Sofia Bergenstråhle och Axel Lennartsson (IP), Tove Lövgren Frisk (Compliance), Ellinor Gyllenhammar and Elin Kollin (VDR).

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024